Pag-aaral pangklinika para sa COPD sa Georgia
12 pag-aaral para sa COPD ang naghahanap ng mga kalahok sa mga site sa Georgia.
Mga Lungsod sa Georgia
Opisyal na teksto ng pag-aaral (English)
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- Private Practice - Dr. David Kavtaradze- Site Number : 8400017, Cordele
Nagre-recruitPhase 4
Edad 40 hanggang 85 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07053423Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Private Practice - Dr. David Kavtaradze- Site Number : 8400006, Cordele
- Primeway Clinical Research- Site Number : 8400121, Fayetteville
Nagre-recruitPhase 3
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07190209Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Appalachian Clinical Research- Site Number : 8400060, Adairsville
Nagre-recruitPhase 3
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07190222A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Atlanta
- Research Site, Cordele
- Research Site, Decatur
- at 1 pa
Nagre-recruitPhase 3
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Atlanta
- Research Site, Lithonia
- Research Site, Rincon
Nagre-recruitPhase 3
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06883305A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Cpcc-Research Llc, East Point
- Centricity Research Rincon Pulmonology, Rincon
Nagre-recruitPhase 2/3
Edad 35 hanggang 80 · Lahat ng kasarian · Na-update Ago 31, 2026 · NCT07363694A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Savannah
- Research Site, Tucker
Nagre-recruitPhase 3
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT06283966To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Centricity Research Columbus, Rincon
Nagre-recruitPhase 2
Edad 40 hanggang 85 · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT07684820eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Cordele
- GSK Investigational Site, Dunwoody
Nagre-recruitPhase 3
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Hul 28, 2026 · NCT07177339Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
- Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur
Nagre-recruitPhase 2
Edad 35 hanggang 89 · Lahat ng kasarian · Na-update May 15, 2026 · NCT05937854Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Adairsville
- GSK Investigational Site, Cordele
- GSK Investigational Site, East Point
- at 1 pa
Nagre-recruitPhase 3
Edad 40 hanggang 80 · Lahat ng kasarian · Na-update Abr 9, 2026 · NCT06961214Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- SpeciCare, Inc, Gainesville
Nagre-recruitObservasyonal na pag-aaral
Edad 50 pataas · Lahat ng kasarian · Na-update Ago 5, 2025 · NCT06122077Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.